A CXCR4 partial agonist improves immunotherapy by targeting polymorphonuclear myeloid-derived suppressor cells and cancer-driven granulopoiesis.
Qian J, Ma C, Waterbury QT, Zhi X, Moon CS, Tu R, Kobayashi H, Wu F, Zheng B, Zeng Y, Zheng H, Ochiai Y, White RA, Harle DW, LaBella JS, Zamechek LB, Hu LZ, Moy RH, Han AS, Daugherty B, Lederman S, Wang TC.
Qian J, et al. Among authors: zhi x.
bioRxiv [Preprint]. 2024 Oct 11:2024.10.09.617228. doi: 10.1101/2024.10.09.617228.
bioRxiv. 2024.
PMID: 39416177
Free PMC article.
Preprint.